Buscar resultados de ensayos clínicos
Polyomavirus Infections - 25 Studies Found
Estado | Estudiar |
Recruiting |
Nombre del estudio: Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation Condición: Merkel Cell Carcinoma Fecha: 2014-06-20 Intervenciones: Drug: Ipilimumab adjuvant treatment of completely resected Merkel cell carcinoma |
Recruiting |
Nombre del estudio: Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200) Condición: Carcinoma, Merkel Cell Fecha: 2014-06-02 Intervenciones: Drug: Avelumab Avelumab will be administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour in |
Recruiting |
Nombre del estudio: F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma Condición: Merkel Cell Carcinoma Fecha: 2014-01-31 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma Condición: Merkel Cell Carcinoma Fecha: 2014-01-10 Intervenciones: Biological: GLA-SE Glucopyranosyl Lipid A in Stable Emulsion |
Withdrawn |
Nombre del estudio: Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma Condición: Merkel Cell Carcinoma Fecha: 2013-07-28 Intervenciones: Drug: Ipilimumab Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is comm |
Terminated |
Nombre del estudio: Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma Condición:
Fecha: 2012-12-27 Intervenciones:
|
Completed |
Nombre del estudio: IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer Condición: Merkel Cell Carcinoma Fecha: 2011-09-23 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: Merkel Positron Emission Tomography (PET) Protocol Condición: Merkel Cell Carcinoma Fecha: 2009-11-12 Intervenciones:
|
Recruiting |
Nombre del estudio: Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma Condición:
Fecha: 2017-03-01 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma Condición:
Fecha: 2013-12-19 Intervenciones: Drug: Cabozantinib Cabozantinib 60 mg Oral Daily 28 days (4 weeks) |